Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-13

FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) from Gilead Sciences, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Genvoya (elvitegravir; cobicistat; emtricitabine; tenofovir alafenamide)

Snippet

SUPPL AP for GENVOYA (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)